Laird Norton Wetherby Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$462K	Buy	4,613 +865	+23%	+$77.9K	0.02%	614
2025 Q2	$311K	Buy	+3,748	New	+$299K	0.01%	710
2024 Q4	$338K	Hold	3,748	–	–	0.02%	663
2024 Q3	$370K	Hold	3,748	–	–	0.02%	660
2024 Q2	$347K	Buy	+3,748	New	+$336K	0.02%	660
2017 Q4	–	Sell	-150	Closed	-$13K	–	677
2017 Q3	$13K	Buy	+150	New	+$12K	﹤0.01%	630

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's XBI Position: Q3 2025 in Review

Laird Norton Wetherby Wealth Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 23% in Q3 2025, buying an estimated $77.9K and bringing the position to 4,613 shares worth $462K. The position accounts for 0.02% of the portfolio, ranked #614.

Laird Norton Wetherby Wealth Management first reported a position in XBI in Q3 2017 and has held it in 6 quarters since. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

Laird Norton Wetherby Wealth Management held 4,613 shares of State Street SPDR S&P Biotech ETF worth $462K as of Q3 2025.
Laird Norton Wetherby Wealth Management bought 865 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $77.9K.
State Street SPDR S&P Biotech ETF made up 0.02% of Laird Norton Wetherby Wealth Management's portfolio in Q3 2025, its #614 holding.
Laird Norton Wetherby Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and has held it in 6 quarters since.
656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.